Overview

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This will be a single arm Phase II study.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborator:
Novartis Pharmaceuticals
Treatments:
Panobinostat